Erythropoietin (EPO), a pleiotropic hormone that has been shown to exert tissue-protective effects via the innate repair receptor (IRR) independent of its hematopoietic properties via the EPO receptor (EPO-R) homodimer (15, 16), appears to be a promising candidate to be further evaluated in HUS. Here, EPOR is linked to hemolytic-uremic syndrome.